

Preliminary Adverse Effects Patient Data

TOTAL	TOTAL	TOTAL	TOTAL
Patients on Therapy	Patients with Clinician Reported Outcomes	Patients with Reported Adverse Effects	% of Patients with Reported Outcomes with AE
455	390	130	33%



Patients on Therapy *	Patients with Clinician Reported Outcomes	Patients with Reported Adverse Effects **	% of Mild, Moderate and Severe Adverse Events Per Therapy		

Trametinib	240	215	47	13%	9%	0.4%
Rapamycin	166	147	29	12%	7.5%	0.6%
Lapatinib	131	120	27	18%	7.5%	0%
Dasatinib	86	76	25	18%	15%	0%
Imatinib	78	62	15	21%	5%	1.5%
Vorinostat	62	54	18	11%	22%	1.9%
Toceranib	49	39	10	33%	7.6%	0%
Crizotinib	7	6	3	50%	17%	0%

- Patients on combination therapies are counted more than once. They are counted for each particular drug
- In 25% of reported AEs, patients were on combination targeted therapies making it difficult to determine which single therapy caused the AE or if the AE was due to the combination. In these cases, the AE was counted for all drugs. It is also unknown what percentage of patients were on additional chemotherapy in combination with targeted therapy.
- Totals are not a sum of all events but total number of patients affected.
- In 83% of reported Rapamycin AEs, the therapy was used in combination with other targeted therapies
- Vorinostat: Early Vorinostat recommendations were at a higher dosage but have since been reduced due to a high rate of adverse events. Following this dose decrease, the number and percentage of AEs has dropped dramatically.

Number and Type of Preliminary Adverse Effects Reported

Trametinib	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
Mild	7%	3%	4%	3%	0.5%
Moderate	4%	1%	5%	3%	1%
Severe	0%	0%	0%	0%	0%

Other less common effects - Anemia, Hemorrhagic Gastroenteritis

Rapamycin	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	7%	5%	5%	3%	0%
	5%	1%	2%	2%	0%
	0%	0%	0%	0%	0%

Other less common effects: Anemia

Lapatinib	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	9%	3%	5%	3%	0%
	3%	1%	3%	3%	0%
	0%	0%	0%	0%	0%

Other less common effects: Progressive Liver Enzyme Elevations, Oral ulcer

Dasatinib	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	8%	8%	9%	4%	0%
	7%	7%	3%	1%	3%
	0%	0%	0%	0%	0%

Other less common effects: Elevated Kidney Values

Imatinib	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	10%	6%	3%	5%	0%
	0%	0%	0%	2%	0%
	2%	2%	0%	2%	0%

Other less common effects: Anemia, Increased Cardiac Toxicity

Vorinostat	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	9%	4%	4%	0%	0%
	17%	17%	7%	4%	0%
	0%	0%	0%	0%	0%

Other less common effects: Seizure, Oral ulcer

Toceranib	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	21%	0%	13%	3%	0%
	3%	5%	8%	3%	0%
	0%	0%	0%	0%	0%

Crizotinib	Diarrhea	Vomiting	Inappetance	Lethargy	Skin Lesions
	0%	0%	33%	17%	0%
	0%	17%	0%	0%	0%
	0%	0%	0%	0%	0%